Enzychem Lifesciences Corp

Enzychem Lifesciences Corp has a market price of 990.0 KRW and a market cap of 74,120,371,380 KRW, with a price-to-book ratio of 0.54 and a price-to-tangible-book ratio of 0.54. The company's enterprise value to EBITDA is -3.93, and its enterprise value to revenue is 1.05, indicating a low valuation relative to revenue. The company's return on equity is -13.18%, and its return on assets is -12.2%, both significantly below the industry median for pharmaceuticals. This suggests poor profitability and asset utilization compared to peers. The company's operating income and net income are both negative, at -18,079,359,770 KRW and -18,131,506,690 KRW, respectively, indicating a loss-making position. Enzychem Lifesciences Corp's revenue is concentrated in the development and manufacture of medical raw materials, with no disclosed segment breakdown. The company's geographic exposure is primarily in Korea, with no significant international revenue disclosed. The lack of segment data limits the ability to assess diversification. The company's revenue for the latest period is 67,750,824,740 KRW, but there is no disclosed growth trajectory or outlook for the current or next fiscal year. The company's operating cash flow is negative at -11,012,139,980 KRW, and its free cash flow is also negative at -15,739,967,710 KRW, indicating liquidity challenges. The company's risk assessment indicates low liquidity and low dilution risk. There are no immediate filing-based liquidity or dilution flags. The company's debt-to-equity ratio is 0.04, and its current ratio is 14.06, suggesting strong short-term liquidity. However, the negative operating and free cash flows indicate potential long-term liquidity concerns. There are no recent events or filings disclosed that would significantly impact the company's operations or financial position. The company's capital expenditure is -779,470,170 KRW, indicating a reduction in capital spending.